文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Aramchol治疗非酒精性脂肪性肝炎:随机双盲安慰剂对照2b期试验

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial.
PubMed 文献 · Nat Med · 2021-10-07

ARREST试验为52周随机双盲安慰剂对照2b期研究,纳入247例NASH患者,评估Aramchol 400mg、600mg与安慰剂。主要终点即600mg组52周磁共振波谱肝甘油三酯下降未达预设显著性(安慰剂校正差值-3.1,95%CI -6.4至0.2,P=0.066),但组织学与ALT改善及安全性为SCD1调控提供依据。

要点

  • Aramchol 600mg降低肝甘油三酯未达预设显著性(P=0.066)。
  • 600mg组NASH缓解且纤维化未恶化比例16.7% vs 安慰剂5%(OR=4.74)。
  • 600mg组ALT安慰剂校正下降-29.1 IU/L(95%CI -41.6至-16.5),安全性良好。

核心结论

  • Aramchol 600mg降低肝脂肪的主要终点未达预设显著性水平,但组织学和酶学变化及安全性支持SCD1调控作为NASH和纤维化的潜在治疗方向。

研究设计与样本

  • ARREST为52周随机双盲安慰剂对照2b期试验,纳入247例NASH患者,随机分配至Aramchol 400mg(n=101)、600mg(n=98)和安慰剂(n=48)组。

主要发现

  • Aramchol 600mg安慰剂校正肝甘油三酯降低-3.1(95%CI -6.4至0.2,P=0.066),未达预设显著性。
  • 600mg组NASH缓解且纤维化未恶化16.7%(13/78) vs 安慰剂5%(2/40),OR=4.74(95%CI 0.99至22.7)。
  • 600mg组纤维化改善≥1期且NASH未恶化29.5% vs 17.5%,OR=1.88(95%CI 0.7至5.0)。
  • 600mg组ALT安慰剂校正下降-29.1 IU/L(95%CI -41.6至-16.5)。
  • 因不良事件提前终止<5%,Aramchol 600mg和400mg安全、耐受良好,组间严重或重度不良事件无失衡。

临床怎么用

  • Aramchol 600mg未达主要终点,暂不能作为NASH常规治疗推荐,需等待正在进行的3期项目结果。

局限性

  • 主要终点未达预设显著性,阻止了进一步正式统计分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonalcoholic steatohepatitis (NASH), a chronic liver disease without an approved therapy, is associated with lipotoxicity and insulin resistance and is a major cause of cirrhosis and hepatocellular carcinoma. Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents and reduced steatosis in an early clinical trial. ARREST, a 52-week, double-blind, placebo-controlled, phase 2b trial randomized 247 patients with NASH (n = 101, n = 98 and n = 48 in the Aramchol 400 mg, 600 mg and placebo arms, respectively; NCT02279524 ). The primary end point was a decrease in hepatic triglycerides by magnetic resonance spectroscopy at 52 weeks with a dose of 600 mg of Aramchol. Key secondary end points included liver histology and alanine aminotransferase (ALT). Aramchol 600 mg produced a placebo-corrected decrease in liver triglycerides without meeting the prespecified significance (-3.1, 95% confidence interval (CI) -6.4 to 0.2, P = 0.066), precluding further formal statistical analysis. NASH resolution without worsening fibrosis was achieved in 16.7% (13 out of 78) of Aramchol 600 mg versus 5% (2 out of 40) of the placebo arm (odds ratio (OR) = 4.74, 95% CI = 0.99 to 22.7) and fibrosis improvement by ≥1 stage without worsening NASH in 29.5% versus 17.5% (OR = 1.88, 95% CI = 0.7 to 5.0), respectively. The placebo-corrected decrease in ALT for 600 mg was -29.1 IU l-1 (95% CI = -41.6 to -16.5). Early termination due to adverse events (AEs) was <5%, and Aramchol 600 and 400 mg were safe, well tolerated and without imbalance in serious or severe AEs between arms. Although the primary end point of a reduction in liver fat did not meet the prespecified significance level with Aramchol 600 mg, the observed safety and changes in liver histology and enzymes provide a rationale for SCD1 modulation as a promising therapy for NASH and fibrosis and are being evaluated in an ongoing phase 3 program.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Ratziu V, de Guevara L, Safadi R, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2021. PMID: 34621052. doi:10.1038/s41591-021-01495-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。